Oncology and Hematology: Archives

SUMMARY AND COMMENT

Sorafenib for Metastatic Renal Cell Cancer

• October 27, 2009
• Robert Dreicer, MD, MS, FACP

Sorafenib had limited activity in patients with sunitinib-refractory disease.

• Reviewing:
• Di Lorenzo G et al., J Clin Oncol 2009 Sep 20; 27:4469

SUMMARY AND COMMENT

Daunorubicin for Younger Adults with Acute Myeloid Leukemia

• October 20, 2009
• Michael E. Williams, MD

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50.

• Reviewing:
• Fernandez HF et al., N Engl J Med 2009 Sep 24; 361:1249

SUMMARY AND COMMENT

Daunorubicin for Older Adults with Acute Myeloid Leukemia

• October 20, 2009
• Michael E. Williams, MD

High-dose daunorubicin improved complete response rates in patients aged 60 and older but did not improve survival overall.

• Reviewing:
• Löwenberg B et al., N Engl J Med 2009 Sep 24; 361:1235 Dombret H and Gardin C., N Engl J Med 2009 Sep 24; 361:1301

SUMMARY AND COMMENT

Erythropoietin for Myelodysplastic Syndromes

• October 20, 2009
• David Green, MD, PhD

Correction of anemia was safe and improved quality of life.

• Reviewing:
• Greenberg PL et al., Blood 2009 Sep 17; 114:2393

SUMMARY AND COMMENT

Androgens, Telomerase, and Aplastic Anemia

• October 20, 2009
• David Green, MD, PhD

Investigators uncovered a potential mechanism for androgen efficacy in aplastic anemia.

• Reviewing:
• Calado RT et al., Blood 2009 Sep 10; 114:2236

SUMMARY AND COMMENT

Can Acupuncture Help Ease Xerostomia?

• October 13, 2009
• Barbara A. Murphy, MD

Acupuncture mitigated symptoms but did not increase salivation.

• Reviewing:
• Garcia MK et al., Head Neck 2009 Oct; 31:1360

SUMMARY AND COMMENT

Conservative Management of Localized Prostate Cancer

• October 13, 2009
• Robert Dreicer, MD, MS, FACP

Disease surveillance might be appropriate in certain men.

• Reviewing:
• Lu-Yao GL et al., JAMA 2009 Sep 16; 302:1202

SUMMARY AND COMMENT

Tailoring Therapies for Lung Cancer

• October 13, 2009
• Lin-Chi Chen, MD, PhD

Identifying gene mutations helped predict responses to tyrosine kinase inhibitors.

• Reviewing:
• Mok TS et al., N Engl J Med 2009 Sep 3; 361:947 Rosell R et al., N Engl J Med 2009 Sep 3; 361:958

SUMMARY AND COMMENT

Dabigatran for Atrial Fibrillation

• October 6, 2009
• David Green, MD, PhD

Compared with warfarin, high-dose dabigatran was associated with fewer strokes but a higher rate of drug discontinuation.

• Reviewing:
• Connolly SJ et al., N Engl J Med 2009 Sep 17; 361:1139

SUMMARY AND COMMENT

Vinflunine for Advanced Urothelial Cancer

• October 6, 2009
• Robert Dreicer, MD, MS, FACP

A 2-month survival advantage was achieved but was not statistically significant.

• Reviewing:
• Bellmunt J et al., J Clin Oncol 2009 Sep 20; 27:4454